3.8 Article

Priorities, actions and risks in the COVID-19 pandemic: a flash SoMe survey among surgical oncologists

期刊

PLEURA AND PERITONEUM
卷 6, 期 1, 页码 7-12

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/pp-2020-0142

关键词

COVID-19; priorities; surgical oncology

向作者/读者索取更多资源

The COVID-19 pandemic has disrupted surgical treatment for cancer patients worldwide, leading surgical oncologists to prioritize saving lives and support lockdown measures. Some modifications in cancer care are considered unacceptable if longer than two weeks.
Objectives: Corona virus-induced disease 19 (COVID-19) pandemic has globally affected the surgical treatment of cancer patients and has challenged the ethical principles of surgical oncologists around the world. Not only treatment but also diagnosis and follow-up have been disrupted. Methods: An online survey was sent through Twitter and by the surgical societies worldwide. The survey consisted of 29 closed-ended questions and was conducted over a period of 24 days beginning in March 26, 2020. Results: Overall, 394 surgical oncologists from 41 different countries answered the questionnaire. The predominant guiding principle was saving lives 240 (62%), and the different aspects of lock-down found hence large support (mean 7.1-9.3 out of 10). Shut-down of elective surgery and modification of cancer care found a mean support of 7.0 +/- 3.0 and 5.8 +/- 3.1, respectively. Modification of cancer care longer than two weeks was considered unacceptable to 114 (29%) responders. Hundred and fifty six (40%) and 138 (36%) expect return to normal beyond six months for surgical practice and cancer care, respectively. Conclusions: Surgical oncologists show strong and longlasting support for lock-down measures aiming to save lives. The impact of the pandemic on surgical oncology is perceived controversially, but the majority was forced already now to accept what is inacceptable for many of their colleagues.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据